LEVERAGING SYNERGISM INDUSTRY-ACADEMIA PARTNERSHIP FOR IMPLEMENTATION OF NATIONAL EDUCATION POLICY 2020

1. LEVERAGING SYNERGISM: INDUSTRY-ACADEMIA PARTNERSHIP FOR
IMPLEMENTATION OF NATIONAL EDUCATION POLICY 2020
Dnyandeep college of pharmacy shitalwadi, ramtek
Date: 06 March 2024
Pragati k. Mahajan

2. Pragati k. Mahajan

3. Education is the most important attribute for
any country to enable it to achieve its full
human potential, developing an equitable and
just society, and promoting overall national
development.
The education sector across the world has
recently observed transformations in the
programme structure and outcomes due to rapid
scientific and technological advancements.
In India, there is a need to focus on universal
access to quality education to reap its
demographic advantage and for maximising
country’s talent and resources.
introduction
Pragati k. Mahajan

4. The National Education Policy–2020, a long time coming, has laid a clear path
for transforming the education system of the country.
AIM
The Policy aims to revolutionize the Indian Higher Education space to catch up
with the global needs of the 21st century.
All these years, India’s policy goals have been primarily focusing on access,
expansion, and specialization with very little focus on skill and holistic
development. The National Education Policy–2020 could break from the past by
including quality, skill development, and multidisciplinary approach as the
critical levers for improving student learning outcomes.
Pragati k. Mahajan

5. 3.Middle stage
(3year)
Class 6-8
Computer code
Vocational subject
Indian language
Secondary stage
(4 year)
Class 9-12
Foreign language
No stream multiple
subject
Semester pattern
Critical thinking
Pragati k. Mahajan

6.  Graduation (4 year)
 1 year --- certificate
 2 year ---diploma
 3 year ---degree (job/competition)
 4 year ---research
 Re-entry
 Post Graduation (1/2year)
 Ph.d ----4 year
 GDP= 6%
Pragati k. Mahajan

7. In the pharmaceutical industry, leveraging synergism involves,
 Integrating the expertise of academia with the resources and research
capabilities of the industry.
 Enhances drug discovery, development, and innovation, accelerating
the translation of academic research into practical applications.
 Addresses healthcare challenges.
 Ensures the effective translation of scientific knowledge into tangible
benefits for society.
Pragati k. Mahajan

8. KeyObjectives
 - Research and Innovation
 - Industry-Academia Collaboration
 - Global Competitiveness
 - Regulatory Reforms
 - Affordable Healthcare
 - Ethical Practices
 - Adapting to Emerging Technologies
 - Environmental Sustainability
Pragati k. Mahajan

9. IMPORTANCE OFCOLLABORATION BETWEEN
INDUSTRYANDACADEMIA
Collaboration between industry and academia
is crucial for bridging the gap between theoretical
knowledge and practical skills.
 It enhances student employability.
 fosters innovation through real-world applications.
 ensures that education aligns with industry demands.
 creating a dynamic synergy that benefits both sectors
and contributes to societal and economic growth.
Pragati k. Mahajan

10. Collabration with academia- industry
Pragati k. Mahajan

11. ESTABLISHINGABRIDGE BETWEENACADEMIAAND
INDUSTRYFOR MUTUALBENEFIT
1. Building Collaborative Frameworks
2. Mutual Learning Initiatives
3. Internship and Apprenticeship Programs
4. Joint Research and Development Projects
5. Industry Experts as Educators
6. Curriculum Design and Review Committees
7. Fostering Innovation Through Collaboration
8. Enhancing Employability Through Practical Exposure
9. Knowledge Exchange Platforms
Pragati k. Mahajan

12. INDUSTRY-ACADEMIAPARTNERSHIP
 An collaborative relationship between academic
institutions (such as universities and research centers) and
industries (private enterprises or sectors), aimed at mutual
benefit through the sharing of knowledge, resources, and
expertise.
 This partnership facilitates the integration of academic
research into practical applications, promotes innovation,
and supports the development of a skilled workforce that
meets industry needs.
 It often involves joint research projects, internships, and
knowledge exchange initiatives to bridge the gap between
theoretical learning and real-world industry demands.
Pragati k. Mahajan

13. SOME EXAMPLES OFCOLLABRATIONS
 GlaxoSmithKline (GSK) and University of Strathclyde
 Pfizer-UCSF Center for Therapeutic Innovation (CTI)
 AstraZeneca and Cambridge University
 Johnson & Johnson Innovation - JLABS and Academic
Medical Centers.
 Sun Pharma and Nagpur University Collaborative
Research Center
 CIPLA and Government Medical College
Collaborative Training Program
 Lupin Limited and National Institute of
Pharmaceutical Education and Research (NIPER),
Nagpur Pragati k. Mahajan

14. SYNERGIES INACTION(1+1=2)
 Joint Drug Discovery Initiatives
 Clinical Trials and Research Consortia
 Technology Transfer and Licensing Agreements
 Internship and Training Programs
 Educational Partnerships and Curriculum Development
 Knowledge Exchange Platforms
 Shared Resources for R&D
 Cross-Appointments and Joint Faculty Positions
Pragati k. Mahajan

15. BENEFITS FOR STUDENTS, RESEARCHERS,AND
INDUSTRIES
Benefits of Industry-Academia Collaboration,
 1. Real-World Exposure for Students.
 2.Enhanced Skill Development Opportunities.
 3. Networking and Career Prospects for Students.
 4. Industry-Relevant Education.
 5.Innovation and Creativity Stimulus for Students.
 6. Access to Resources for Researchers.
 7. Collaborative Research Opportunities for Researchers.
 8. Professional Development and Faster Application of Research
for Industries. Pragati k. Mahajan

16. Pragati k. Mahajan

17. ALIGNING WITH NEP2020
 Pharma industry-academia partnerships align seamlessly with the
goals of the National Education Policy 2020 (NEP).
 NEP emphasizes holistic education, practical skill development, and
industry integration.
 Collaborations bridge theory and practice.
 encourages flexible curriculum design, echoing the adaptable nature
of industry-academia collaborations.
 mirroring the cross-functional approaches in pharmaceutical research.
Pragati k. Mahajan

18. In summary, the future of pharma industry-academia collaborations
presents a landscape rich with technological advancements, adaptive
educational strategies, and innovative approaches to global health
challenges
These developments align seamlessly with the objectives of the
National Education Policy 2020 (NEP 2020), emphasizing the need for
real-world exposure, skill enhancement, and innovation in education.
Leveraging synergism between industry and academia is not just a
pathway to successful collaboration but a cornerstone for the effective
implementation of NEP 2020.
By fostering collaboration, these initiatives contribute not only to the
growth of the pharmaceutical industry but also to the nation's health and
economic prosperity, creating a symbiotic relationship that propels
advancements in education, research, and healthcare.
OVERVIEW
Pragati k. Mahajan

19. Pragati k. Mahajan